A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel

被引：0
|
作者：
Chi, K. N.
Beardsley, E. K.
Venner, P. M.
Eigl, B. J.
Hotte, S. J.
Ko, Y.
Saad, F.
Winquist, E.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] Tom Baker Canc Clin, Calgary, AB, Canada
[4] Juravinski Canc Ctr, Hamilton, ON, Canada
[5] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] London Hlth Sci Ctr, London, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5166
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [32] Phase II study combining gefitinib with etoposide in patients with hormone-refractory metastatic prostate cancer (mHRPC) after docetaxel-based therapy
    Hauke, R. J.
    Loberiza, F. R.
    Elkahwaji, J. E.
    Townley, P. M.
    Bascom, G. K.
    Lin, M.
    Batra, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] A retrospective analysis on 35 patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Carlini, P.
    Felici, A.
    Ruggeri, E. M.
    Moscetti, L.
    Chilelli, M.
    Ciccarese, M.
    Pino, M. S.
    Cecere, F. L.
    Nuzzo, C.
    Sperduti, I
    Pollera, C. F.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [34] Weekly docetaxel for advanced hormone-refractory prostate cancer-hrpc
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 187 - 187
  • [35] A phase II study of sorafenib in combination with bicalutamide in patients with chemo-naive hormone refractory prostate cancer (HRPC)
    Beardsley, E. K.
    Ellard, S. L.
    Holte, S. J.
    North, S. A.
    Winquist, E.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] A dose-escalating phase I study of biweekly docetaxel in older men with hormone refractory prostate cancer (HRPC)
    McDevitt, J.
    Hauser, R.
    Simon, J.
    Balducci, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [38] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
  • [39] A phase II clinical study of high-dose calcitriol plus docetaxel and zoledronic acid in hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [40] Phase II randomized trial of docetaxel plus estramustine (BE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): A final report.
    Eymard, JC
    Joly, F
    Priou, F
    Zannetti, A
    Ravaud, A
    Kerbrat, P
    Mousseau, M
    Paule, B
    Touze, F
    Ecstein-Fraisse, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
12345